These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. Oestereich L; Rieger T; Neumann M; Bernreuther C; Lehmann M; Krasemann S; Wurr S; Emmerich P; de Lamballerie X; Ölschläger S; Günther S PLoS Negl Trop Dis; 2014 May; 8(5):e2804. PubMed ID: 24786461 [TBL] [Abstract][Full Text] [Related]
8. Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates. Madelain V; Duthey A; Mentré F; Jacquot F; Solas C; Lacarelle B; Vallvé A; Barron S; Barrot L; Mundweiler S; Thomas D; Carbonnelle C; Raoul H; de Lamballerie X; Guedj J Antiviral Res; 2020 May; 177():104758. PubMed ID: 32135218 [TBL] [Abstract][Full Text] [Related]
9. Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Gowen BB; Westover JB; Sefing EJ; Van Wettere AJ; Bailey KW; Wandersee L; Komeno T; Furuta Y Antiviral Res; 2017 Sep; 145():131-135. PubMed ID: 28780425 [TBL] [Abstract][Full Text] [Related]
10. Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. Madelain V; Guedj J; Mentré F; Nguyen TH; Jacquot F; Oestereich L; Kadota T; Yamada K; Taburet AM; de Lamballerie X; Raoul H Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27736754 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Oestereich L; Lüdtke A; Wurr S; Rieger T; Muñoz-Fontela C; Günther S Antiviral Res; 2014 May; 105():17-21. PubMed ID: 24583123 [TBL] [Abstract][Full Text] [Related]
12. Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Hawman DW; Haddock E; Meade-White K; Williamson B; Hanley PW; Rosenke K; Komeno T; Furuta Y; Gowen BB; Feldmann H Antiviral Res; 2018 Sep; 157():18-26. PubMed ID: 29936152 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model. Zhu W; Zhang Z; He S; Wong G; Banadyga L; Qiu X Antiviral Res; 2018 Mar; 151():39-49. PubMed ID: 29369776 [TBL] [Abstract][Full Text] [Related]
15. Lassa fever. Effective therapy with ribavirin. McCormick JB; King IJ; Webb PA; Scribner CL; Craven RB; Johnson KM; Elliott LH; Belmont-Williams R N Engl J Med; 1986 Jan; 314(1):20-6. PubMed ID: 3940312 [TBL] [Abstract][Full Text] [Related]
16. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. Mendenhall M; Russell A; Smee DF; Hall JO; Skirpstunas R; Furuta Y; Gowen BB PLoS Negl Trop Dis; 2011 Oct; 5(10):e1342. PubMed ID: 22022624 [TBL] [Abstract][Full Text] [Related]
17. Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens. Pires de Mello CP; Tao X; Kim TH; Bulitta JB; Rodriquez JL; Pomeroy JJ; Brown AN Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109164 [TBL] [Abstract][Full Text] [Related]
18. Favipiravir: a new medication for the Ebola virus disease pandemic. Nagata T; Lefor AK; Hasegawa M; Ishii M Disaster Med Public Health Prep; 2015 Feb; 9(1):79-81. PubMed ID: 25544306 [TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of favipiravir (T-705) against mammalian and avian bornaviruses. Tokunaga T; Yamamoto Y; Sakai M; Tomonaga K; Honda T Antiviral Res; 2017 Jul; 143():237-245. PubMed ID: 28465146 [TBL] [Abstract][Full Text] [Related]